SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-24-015447
Filing Date
2024-03-27
Accepted
2024-03-27 07:01:07
Documents
8
Period of Report
2024-05-20

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20018253x1_def14a.htm DEF 14A 904251
2 ny20018253x1_barchart01.jpg GRAPHIC 161673
3 ny20018253x1_barchart02.jpg GRAPHIC 150609
4 ny20018253x1_chart01.jpg GRAPHIC 257475
5 ny20018253x1_piechart01x2.jpg GRAPHIC 76154
6 ny20018253x1_pc01.jpg GRAPHIC 588709
7 ny20018253x1_pc02.jpg GRAPHIC 551733
8 sig_arthursandsx1.jpg GRAPHIC 16879
  Complete submission text file 0001140361-24-015447.txt   3387299
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: DEF 14A | Act: 34 | File No.: 001-39398 | Film No.: 24785738
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)